Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCMKTS:MVMDF) (FRA:20MP) said it has executed an agreement to conduct its Bio Safety Level 4 (BSL-40) lab study of coronavirus (COVID-19) viral clearance in transgenic mice.
The company said the study is designed to prove the superiority of its solubilized Ivermectin technology versus a commercially available oral form in speed and efficacy of viral clearance.
“This is a very significant project for MVMD and it will clearly demonstrate how our solubility technology applied to the Ivermectin drug can be applied as a broad therapeutic to immediately treat COVID-19, as well as its role in stopping the deadly spread of future pandemics that are certain to follow,” Mountain Valley MD CEO Dennis Hancock said in a statement.
READ: Mountain Valley MD looking to eradicate needles with its patented Quicksome oral drug delivery technology
He added: “Quicksol allows us to imagine a world's first as an injectable Ivermectin format for emergency front line usage as well as a rapid dissolve tablet that is administered for prevention like vitamin C around the world.”
Mountain Valley MD noted that there are less than 30 BSL-4 facilities in the world capable of performing the study, which is expected to begin in late February 2021. It said the study results are expected in April 2021.
The company also said the study, which will be led it's key scientific advisor Dr John Clements, will be the first of its kind ever conducted with human-grade solubilized Ivermectin anywhere in the world.
“The transgenic mice model was selected to specifically enable preclinical evaluation of the potential therapeutics and monoclonal antibodies and molecular-based therapeutics as they apply to COVID-19 treatments,” Dr Clements commented.
He added: “We designed the study with the goal of providing the first in vivo proof of enhanced COVID-19 viral clearance ability using both the oral sublingual product and the intramuscular injection product using MVMD's Quicksol technology.”
As well, Mountain Valley MD noted that the upcoming BSL-4 lab study will demonstrate meaningful dose sparing in two important ways: a reduction in the required Active Pharmaceutical Ingredient (API) Ivermectin due to the applications of the company's technology; and the shorter course to complete viral clearance.
The company said its solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.
Contact Sean at email@example.com